An Act Establishing A Captive Insurance Company To Administer A Bulk Purchase And Distribution Of Glucagon-like Peptide-1 Prescription Drugs To Qualifying Individuals In This State To Treat Obesity.
Summary
HB 5485 would amend title 38a of the general statutes to create a captive insurance company for a state-run bulk purchasing and distribution program for glucagon-like peptide-1 (GLP-1) prescription drugs used to treat obesity. The bill directs that the captive insurance company be supported by a $10 million appropriation from the General Fund for fiscal year 2026.
Under the proposal, the captive insurance company would buy GLP-1 receptor antagonist drugs in bulk from manufacturers and then distribute them to qualifying Connecticut residents who meet a means-tested eligibility process and who cannot obtain the drugs through their own health insurance. The bill is aimed at expanding access to obesity treatment medications for residents who otherwise face coverage or affordability barriers.
Impact
If enacted, the bill would add a new state-created captive insurance entity within Connecticut’s insurance framework and authorize a dedicated appropriation for drug purchasing and distribution. It would affect title 38a of the general statutes by establishing a mechanism for the state to intervene in the prescription drug market, specifically for obesity-related GLP-1 medications, and would create a new pathway for eligible residents to receive these drugs outside of traditional insurer coverage.
Sentiment
No committee transcript or vote record is available in the provided materials, so there is no documented floor or committee sentiment to summarize. Based on the bill text alone, the proposal appears policy-driven and targeted at improving access to obesity medications, but the record provided does not show formal support, opposition, or amendments.
Contention
The main points of potential contention are likely to be the use of $10 million in General Fund money, the creation of a state-supported captive insurance company, and the decision to provide public assistance for GLP-1 obesity drugs rather than other health priorities. Possible concerns may include cost, fairness of means-testing, whether the state should intervene in pharmaceutical purchasing, and whether residents should receive these medications when private insurance does not cover them. No specific objections or supporters are identified in the available discussion record.